Mercaptopurine

Generic Name: Mercaptopurine

Brand Names: Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)

Drug Type: Small Molecule

Chemical Formula: C_₅H_₄N_₄S

CAS Number: 50-44-2

Unique Ingredient Identifier: PKK6MUZ20G

Background: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

Indication: For remission induction and maintenance therapy of acute lymphatic leukemia.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis

Clinical Trials

A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Drug: Daunorubicin
Drug: Vincristine
Drug: Prednisone
Drug: PEG-Asparaginase
Drug: Methotrexate
Drug: 6-MP (6-Mercaptopurine)
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Leucovorin
Drug: Dexamethasone
Other: Blood draw
Device: CT/PET scans

First Posted Date: 2013-08-12

Last Posted Date: 2025-02-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01920737

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Phase 2

Completed

Conditions: Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood B-Lymphoblastic Lymphoma

Interventions: Drug: dexamethasone
Drug: vincristine sulfate
Biological: rituximab
Drug: clofarabine
Drug: cyclophosphamide
Drug: etoposide
Biological: aldesleukin
Drug: pegaspargase
Drug: methotrexate
Drug: mercaptopurine
Drug: cytarabine
Drug: mitoxantrone
Drug: teniposide
Drug: vinblastine
Biological: natural killer cell infusion
Other: laboratory biomarker analysis
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: therapeutic hydrocortisone
Device: CliniMACS

First Posted Date: 2012-10-04

Last Posted Date: 2022-09-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 80

Registration Number: NCT01700946

Locations: 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Mercaptopurine 20mg/ml oral suspension
Drug: Mercaptopurine 50mg tablet

First Posted Date: 2012-10-02

Last Posted Date: 2013-12-02

Lead Sponsor: Nova Laboratories Limited

Target Recruit Count: 70

Registration Number: NCT01697020

Locations: 🇿🇦
Parexel International, Bloemfontein Early Phase Clinical Unit, Bloemfontein, South Africa

Adalimumab for the Management of Post-operative Crohn's Disease (CD)

Phase 3

Conditions: Crohn Disease

Interventions: Drug: 6 Mercaptopurine
Drug: Adalimumab

First Posted Date: 2012-06-27

Last Posted Date: 2012-06-27

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 100

Registration Number: NCT01629628

Locations: 🇮🇱
Department of Gastroenterology and Liver Diseases, Tel-Aviv Soursky Medical Center, Tel-Aviv, Israel

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Behavioral: Behavioral Intervention
Behavioral: Compliance Monitoring
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Other: Questionnaire Administration
Procedure: Standard Follow-Up Care

First Posted Date: 2012-01-04

Last Posted Date: 2024-08-30

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 570

Registration Number: NCT01503632

Locations: 🇺🇸
Advocate Lutheran General Hospital, Park Ridge, Illinois, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

and more 99 locations

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Lymphoblastic Lymphoma

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Daunorubicin
Drug: PEG-asparaginase
Drug: Erwinia asparaginase
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Thioguanine
Drug: Clofarabine
Drug: Methotrexate
Drug: Mercaptopurine
Drug: Dexamethasone
Drug: Hydrocortisone
Drug: Etoposide

First Posted Date: 2011-10-13

Last Posted Date: 2022-06-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 23

Registration Number: NCT01451515

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours

Phase 2

Completed

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: 6-Mercaptopurine
Drug: Methotrexate

First Posted Date: 2011-09-12

Last Posted Date: 2019-07-09

Lead Sponsor: University of Oxford

Target Recruit Count: 74

Registration Number: NCT01432145

Locations: 🇬🇧
Churchill Hospital, Oxford, United Kingdom

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Recurrent Burkitt Lymphoma
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Burkitt-Like Lymphoma With 11q Aberration
Recurrent B Acute Lymphoblastic Leukemia
High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory B Acute Lymphoblastic Leukemia
Refractory Burkitt Lymphoma
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1